Cannabis Investments

Cannabis Science Receives New Photos and Information on Patient Three’s Previous Examinations and the Current Progress on his Severe Squamous Cell Carcinoma

May 16, 2012

COLORADO SPRINGS –(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to provide the latest photos and information on patient three’s progress.

Cannabis Science continues to work closely with its third patient, who is self-treating his otherwise resistant Squamous Cell Carcinoma. The patient has seen dramatic improvements. He has been applying a topical cannabis extract to his cancer, and has seen a large reduction in the tumor masses. Dr. Melamede spoke with the patient this morning, who stated that 80% of the rim that remained from the large tumor on the left side of his head was now gone. The newly posted photo was from over a week ago.

After his last visit to his oncologist (prior to the newly posted photo), the physician explained that he is concerned there may be more tumors on his head that have not yet manifested. The oncologist then instructed the patient to apply the cannabis extracts to his entire scalp. As a result of more extensive topical application of the medicine, new areas have reemerged and are also dying. For example, a new tumor emerged below his hairline. He treated that tumor in the same manner as he has treated the others. He reported that the new tumor had fallen off and left a small hole, similar to what had occurred on his arm (we have not shown these tumors). The rise and fall of the new tumor will be photo-documented when we receive new photos.

Despite the severe pain resulting from additional exposed areas as more tumor mass dies, he is happy to have chosen this route of treatment as opposed to surgery that would have remove most of his scalp and a good portion of the top of his skull. In order to help with the pain and allow for better sleep, the patient is also now taking the extract internally.

The patient stated, “As for my head… the oncologist was amazed by the progress…. as the one tumor on my right side is now almost down to conforming with the natural shape of my head and he thinks the others are being killed off too but predicted it might be a couple more months before he could declare it works…Cautious optimism. Also the doctor said that he is hopeful that this works, as there is no known chemo that cures this type of cancer.”

You can view these new photos on the Cannabis Science website www.cannabisscience.com and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success.” You can read more news on this 3rd patient as well on the Cannabis Science website at www.cannabisscience.com and click on the breaking news button where you will find all the cancer related and updated patient news.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com

Cannabis Science Inc.
Robert Kane

VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Supports House Minority Leader Nancy Pelosi Historic Statement to President Obama Supporting Medical Cannabis and The Fight for Patient Rights

May 4, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS.ob – News), a pioneering U.S. biotech company developing pharmaceutical cannabis products, supports House Minority Leader Nancy Pelosi D-San Francisco Historic Statement to President Obama supporting Medical Cannabis and the Fight for Patient Rights.

Quoted in several news sources including but not limited to the following:

The Huffington Post:
http://www.huffingtonpost.com/2012/05/03/nancy-pelosi-medical-marijuana_n_1474854.html?ref=politics

and MediaNews Group:
http://www.ibabuzz.com/politics/2012/05/03/pelosi-has-strong-concerns-about-marijuana-raids/

House Minority Leader Nancy Pelosi D-San Francisco Historic Statement to President Obama stated the following:

“Access to medicinal marijuana for individuals who are ill or enduring difficult and painful therapies is both a medical and a states’ rights issue. Sixteen states, including our home state of California and the District of Columbia have adopted medicinal marijuana laws – most by a vote of the people.

I have strong concerns about the recent actions by the federal government that threatens the safe access of medicinal marijuana to alleviate the suffering of patients in California, and undermine a policy that has been in place under which the federal government did not pursue individuals whose actions complied with state laws providing for medicinal marijuana.

Proven medicinal uses of marijuana include improving the quality of life for patients with cancer, HIV/AIDS, multiple sclerosis, and other severe medical conditions.

I am pleased to join organizations that support legal access to medicinal marijuana, including the American Nurses Association, the Lymphoma Foundation of America, and the AIDS Action Council.

Medicinal marijuana alleviates some of the most debilitating symptoms of AIDS, including pain, wasting, and nausea. The opportunity to ease the suffering of people who are seriously ill or enduring difficult and painful therapies is an opportunity we must not ignore.

For these reasons, I have long supported efforts in Congress to advocate federal policies that recognize the scientific evidence and clinical research demonstrating the medical benefits of medicinal marijuana, that respects the wishes of the states in providing relief to ill individuals, and that prevents the federal government from acting to harm the safe access of medicinal marijuana provided under state law. I will continue to strongly support those efforts.”

Dr. Robert Melamede stated, “It’s about time members of congress spoke out in favor of democracy. The people in states like California and Colorado have spoken through their ballots, the very basis of democracy. This is a presidential election year. As soon as the voting public demands medical marijuana as a condition for election, things will rapidly change. We are not surprised by Nancy Pelosi’s statement in view of the low approval ratings that our politicians have. We expect to continue to see more and more politicians come out in favor of the Medical Cannabis industry over the next few months. Let’s face it, prohibition and its associated black market is a source of funding for terrorism and therefore should be illegal.

Our internal models suggest that the medical cannabis industry may lower unemployment by 11.6% or more and increase GDP. The Cannabis Industry can help our great country while at the same time help people with Cancer and help soldiers with PTSD. All of these topics are election issues, which tie into the Medical Cannabis Industry and should have a positive impact on Cannabis Science.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science
Robert Kane
Vice President of Investor Relations
rkane@cannabisscience.com
561-234-6929
or
Dr. Robert Melamede, Ph.D.
President
www.cannabisscience.com
info@cannabisscience.com
1-888-889-0888

View full post on News Releases

Cannabis Science Teams with Dr. Ivan Goldsmith of Trimcare in Las Vegas for Innovative Weight Loss Programs Based on Research of the Endocannabinoid System

May 3, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to welcome Dr. Ivan Goldsmith of Trimcare in Las Vegas, Nevada, into the fold. Cannabis Science and Dr. Goldsmith are teaming up to implement novel treatments for obesity, metabolic syndrome, and hormone deficiency syndromes, backed by the research and science by Cannabis Science and Dr. Goldsmith. He sits as the Nevada state representative on the scientific advisory board for Cannabis Science.

Dr. Goldsmith is a leading medical authority on weight management and patient self-esteem issues. He brings with him 20 years of experience, as well as being triple board certified in Internal Medicine, Anti-aging, and Bariatrics. His company, Trimcare, has treated in excess of 25,000 Las Vegans. The weight loss program includes medication targeting appetite suppression and increasing the body’s natural energy for effective metabolism, as well as meal programs. Trimcare’s philosophy has been to utilize alternative complementary medicine. With Cannabis Science, Trimcare will be actively involved in implementing breakthroughs from cutting edge research on the endocannabinoid system. Not only will weight loss be targeted, but other ailments such as chronic pain, anti-aging, and infectious and metabolic disorders.

Trimcare also focuses on cosmetic procedures, a unique diet based on the patient’s DNA and customized to the patient’s genotype, and hormonal replacement therapy, and smoking cessation. You can learn more about Trimcare at their website, www.trimcare.com.

Dr. Goldsmith says about this new relationship, “We have been pioneers in the implementation of novel treatments for obesity, metabolic syndrome and hormone deficiency syndromes. Our mission has been to enhance wellness and life expectancy through product offerings that encourage patients to participate with us in this journey.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Makes Medical Moves at The 7th Patients Out of Time medical cannabis conference in Tucson at the Loews Ventana Canyon Resort

April 30, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB: CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, was honored to be the Sponsor and an Exhibitor at the 7th national Patients Out of Time, medical cannabis conference in Tucson, Arizona. The conference was attended by patients, doctors, nurses, pharmacists, professors, supporters, and entrepreneurs of the medical cannabis industry. Our own Dr. Melamede presented patient’s results that we have documented at www.cannabisscience.com.

The University of California, San Francisco School of Medicine (UCSF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Patients Out of Time is the only accredited CME program to educate medical professionals about cannabis as a medicine. There were over 25 world-renowned doctors and scientists sharing and presenting the latest research advances as the complexity of the endo-cannabinoid system continues to unfold. Please see the previous news release from April 17, 2012 at http://finance.yahoo.com/news/dr-robert-melamede-scheduled-speak-182800051.html.

Speakers at the conference focused on the science and medicine of cannabinoids. Cannabis Science was overwhelmed, with great feedback by various representatives in the medical community. Prominent speakers included Dr. Robert Melamede, CEO and president of Cannabis Science; Dr. William Courtney of Cannabis Science’s scientific advisory board, and Dr. Andrew Weil, best selling author, speaker, and Integrative Medicine thought-leader. Talks covered specific ailments such as PTSD, cancer, and even drug addiction; research on cannabinoid science and medical applications, and law. Dr. Robert Melamede shared pictures show on our website. Cannabis Science helps cancer patients make informed choices regarding treatments. He also spoke as to the holistic nature by which the endocannabinoid system regulated homeostasis in all vertebrates from conception till death and therefore, why cannabis-based medicines are different from all others in their ability to help with so many illnesses.

Cannabis Science demonstrated a pre-release our multi-tiered, digital educational platform to be announced in more detail later this week. Our novel platform will help to meet the ever-expanding interest in cannabis that is coming from the medical communities as the almost miraculous medical benefits of cannabis emerge from the states that support medical marijuana. Our new educational platform (see below) will bring in revenues as we fill the emerging educational need of the medical community. Realistic cannabis education programs are not currently available in the professional schools that need them to end the disconnect between medical cannabis patients an their physicians.

At the conference the Cannabis Science booth collected data from attendees interested in Cannabis Science Stock and there was a lot of interest in our new branding platform. Attendees were given PR Packets with CBIS information on cancer, Alzheimer’s, PTSD, aging, and heart disease. CBIS had attendees fill out a questionnaire to enter into a drawing for an iPad 3, a symbolic prize since Cannabis Science will launce our new digital education platform for Physicians, on the Apple iPad platform. Our congratulations to our conference iPad winner.

Andrew Pitsicalis, the Branding and Licensing Director for Cannabis Science, revealed the new digital platform and demonstrated the technology at the CBIS booth. Pitsicalis coordinated many interviews with Cannabis Planet TV, Arizona Clinics TV, The Phoenix Arizona Times, and local news and media. As a result, we had the honor to meet with a brain cancer survivor of an extremely dangerous surgery. In December of last year, he had a second operation to try to reduce the large mass in his brain. With stage 4 cancer, he came to Cannabis Science to help us create awareness for other cancer patients worldwide so that they too might understand there is hope with cannabis. The patient had not been a previous cannabis user, and was amazed at the impact the plant had on him. In fact, it prevented him from taking his own life, when he was no longer able to cope with having multiple grand mal seizures daily. The patients close friend begged him to smoke cannabis. When he did, he stopped having seizures. He told us he drove 7 hours to meet Dr. Robert Melamede because he was watching his videos our website and YouTube and found hope. The patient wanted to go to the conference to meet him and other doctors and scientists attending the conference.

The Patients Out of Time charity benefit dinner included entertainment by Greta Gaines from her upcoming album “Grassy Girl;” a live and silent auction, and a guest appearance by Gigi Ganjay. Greta’s information may be found at www.gretagaines.com, www.cannibuzz.com, and her reel at http://www.conlincasting.net/Gretareel/Greta_Gaines/Reel.html Greta Gaines is a client of Kaneabis (a Cannabis Science company).

If you would like to view information that Cannabis Science provided to the attendees of the conference, please visit our website.

Dr. Robert Melamede stated, “Things have never been better for Cannabis Science and this was confirmed at the conference this past weekend. Not only were we part of an historic event with Patients Out of Time, the amount of consciousness and knowledge gained by everyone attending will shape the medicinal science of the industry going forward. Furthermore, our network of professionals increased substantially as we continue to grow the Cannabis Science business model. Most importantly, this conference was a success because it was about the patients, and we heard dramatic testimonials from them, It was all about doing the right things, with the right people, for the right reasons.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
Vice President of Investor Relations
561-234-6929
rkane@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Provides Product Line Guidance With Summary of Products In Development And Available On The Market Today

April 24, 2012

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (CBIS.OB – News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is providing an update and summary of our goals and product line advancements. Some products are currently available to patients with legal state medical marijuana access, and others are up and coming over-the-counter products that will be available to the public nationally and internationally.

Cannabis Science is currently working towards making critical cannabis-based medications more widely available. To this aim, we have initiated, with our FDA advisory group, the pre-IND process. Unlike most conventional treatments, cannabis medicines and formulations have an outstanding safety profile, going back thousands of years. They allow patients in states with medical cannabis laws to safely make informed decisions to legally self-administer various cannabis-based preparations.

The medication will specifically target skin cancers including basal and squamous cell carcinomas. Judging by the results of the squamous cell carcinoma treatment studies Cannabis Science has already undertaken (see cannabisscience.com), we believe we have a breakthrough treatment for squamous cell carcinomas that are resistant to convention chemo- and radiation therapies.

Currently, Cannabis Science has cannabis-based, high quality oil available in Pueblo and Denver Colorado through licensing agreements. The oil, is packaged in oral dispensing syringes for patient self-administration. We have received excellent feedback regarding these products, specifically from patients suffering cancer and chronic pain.

In addition to the license agreements with dispensary and FDA products, Cannabis Science is very excited about the over the counter skin and nutraceutical product lines that are currently in development. Sunscreen, skin and face moisturizer, lip balm, and anti-aging serum will be available over the counter in drugstores and other retail outlets. Dr. Moe Afaneh, Cannabis Science’s Chief Operations Officer, is heading the development of this product line, and with his decade of successful experience in pharmaceutical product marketing, branding, and compounding prescriptions, he is aiding Cannabis Science tremendously in moving these projects forward. Cannabis Science is also in final discussions to finalize the brand name for the initial product line.

The Company’s intent is to work with specially appointed legal providers and laboratories to expand the availability of its formulations across the United States and the world where legally available.

Dr. Bob Melamede stated “Cannabis Science is excited that we are developing profit centers that will come online and create revenue in 2012. In addition to the revenues that we believe will be created with the Cannabis Extract Based prescription medicines and over-the-counter formulations, Cannabis Science has the ability to generate revenues now through the partnership with Vincent Mehdizadeh of Medical Dispensing Solutions, and consulting revenues Kaneabis acquisition. It is our goal to self- fund the FDA IND application and approval process as much as possible, that funding is generated from these additional profit centers.”

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com

View full post on News Releases